Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 3Recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 4

Interventions

Docetaxel 229Radiotherapy 206Magnetic Resonance Spectroscopy 204Radiosurgery 176Gemcitabine 155pembrolizumab 151Nivolumab 147enzalutamide 140Prednisone 129Cisplatin 123Leuprolide 119Androgen Antagonists 117Abiraterone Acetate 114Sunitinib 106Specimen Handling 94Surveys and Questionnaires 91Goserelin 91bicalutamide 90Carboplatin 88Ipilimumab 82gallium 68 PSMA-11 80Blood Specimen Collection 78Everolimus 73apalutamide 72Radiation 71Standard of Care 68Biopsy 68acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 66Paclitaxel 64Cyclophosphamide 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Pyruvic Acid × Genitourinary × Clear all
NCT06384222 2025-12-30

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

University of California, San Francisco

Phase 2 Recruiting
32 enrolled
Genitourinary

Prostatic Neoplasms

NCT02913131 2022-04-22

Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies

University of California, San Francisco

Phase 1/2 Terminated
23 enrolled 6 charts
Genitourinary

Prostatic Neoplasms

NCT02911467 2020-07-24

MR

University of California, San Francisco

Phase 1 Terminated
8 enrolled
Genitourinary

Prostatic Neoplasms

NCT02450201 2018-10-23

MRI With C13 Pilot Study Prostate Cancer

University of California, San Francisco

Phase EARLY_PHASE1 Terminated
5 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡